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Abstract	  
Background:	   The	   appearance	   of	   symptoms	   compatible	   with	   systemic	   autoimmune	   diseases	   has	   been	   described	   in	  
relation	   to	   several	   viral	   infections	   like	  HIV,	   cytomegalovirus	  and	  especially	  PVB19,	  depending	  on	   the	  evolution	  of	   the	  
immunological	  condition	  of	  the	  host	  and	  their	  age.	  We	  present	  a	  young	  immunocompetent	  male	  patient,	  with	  clinical	  
manifestations	  simulating	  systemic	  lupus	  erythematosus	  (SLE)	  with	  important	  activation	  of	  cytokines.	  
	  
Methods:	  For	  quantification	  of	  the	  different	  cytokines	  in	  plasma,	  a	  commercially	  available	  multiplex	  bead	  immunoassay,	  
based	  on	  the	  Luminex	  platform	  (Cat	  #	  HSCYTO-­‐60SK-­‐08,	  Milliplex®	  MAP	  High	  Sensitivity,	  Millipore),	  was	  used	  according	  
to	  the	  manufacturer’s	  instructions.	  All	  samples	  were	  run	  in	  duplicate	  and	  the	  data	  (mean	  fluorescence	  intensity)	  were	  
analyzed	  using	  a	  Luminex	  reader.	  The	  mean	  concentration	  was	  calculated	  using	  a	  standard	  curve.	  
	  
Results:	  The	  clinical	  evolution	  was	  favourable	  without	  the	  need	  for	  any	  specific	  treatment,	  showing	  complete	  recovery	  
after	  two	  months.	  Whilst	  the	  symptoms	  and	  viral	  charge	  were	  disappearing,	  the	  anti-­‐DNA	  continued	  to	  increase	  and	  we	  
demonstrate	   important	   activation	  of	   IL-­‐10,	   IL-­‐6	   and	   TNFα	   cytokines	   as	   a	   result	   of	   a	   hyperstimulating	   response	  by	   an	  
immunocompetent	   hyperfunctional	   system,	   which	   persists	   after	   clinical	   improvement.	   We	   should	   emphasize	   the	  
behaviour	  of	  two	  cytokines:	  IL-­‐12p70	  and	  IL-­‐2,	  which	  showed	  opposite	  tendencies.	  
	  
Conclusions:	   Viral	   infections,	   especially	   PVB19,	   can	   produce	   or	   simulate	   several	   autoimmune	   diseases	   as	   a	  
hyperstimulation	  response	  from	  an	  immunocompetent	  hyperfunctional	  system.	  Consequently,	  a	  persistent	  increase	  of	  
autoantobodies	   and	   important	   activation	   of	   cytokines,	   even	   after	   clinical	   improvement	   and	   seroconversion,	   can	   be	  
demonstrated.	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Introduction	  
Parvovirus	  B19	  (PVB19),	  a	  member	  of	  the	  Parvoviridae	  family	  (gen.	  Erythrovirus),	  was	  accidentally	  discovered	  in	  1975	  by	  
Cossart	  et	  al.	  and	  the	  first	  clinical	  communication	  of	  infection	  appeared	  in	  1981	  [1–3].	  
In	   young	   adults,	   the	   prevalence	   of	   PVB19	   infection	   is	   estimated	   to	   be	   between	   30%	   and	   60%,	   and	   in	   the	   elderly	  
population	  it	  may	  even	  reach	  90%.	  It	  is	  more	  common	  in	  women	  than	  in	  men.	  PVB19	  is	  highly	  contagious.	  Even	  though	  
infections	  appear	  throughout	  the	  year,	  they	  are	  more	  frequent	  in	  spring	  and	  summer.	   	  
Transmission	  of	  the	  infection	  can	  take	  place	  through	  the	  respiratory	  tract,	  blood	  transfusions	  and	  haemoderivatives,	  as	  
well	  as	  vertical	  transmission	  from	  mother	  to	  foetus.	  Fomite	  transmission	  cannot	  be	  ruled	  out	  because	  of	  the	  virus’s	  high	  
resistance	   to	   inactivation.	   Viraemia	   takes	   place	   between	   7	   and	   10	   days	   after	   exposure,	   and	   the	   patient	   can	   be	  
contagious	  before	  symptoms	  appear	  and	  until	  they	  do	  [4,	  5].	  
Clinical	  manifestations	  may	  vary	  from	  one	  patient	  to	  another,	  mainly	  depending	  on	  the	  immunological	  condition	  of	  the	  
host	  and	  their	  age.	  This	  makes	   it	  difficult	  to	  diagnose	   in	   immunocompetent	  adults	  since	   it	  may	  develop	   in	  an	  atypical	  
way	  or	  even	  be	  asymptomatic.	   	  
In	  50%	  of	  cases,	  it	  appears	  to	  be	  simply	  a	  common	  cold	  (body	  malaise,	  fever	  and	  muscular	  pain)	  and	  only	  25%	  of	  cases	  
include	  the	  classic	  symptoms	  of	  exanthema,	  mild	  cytopenia	  (especially	  anaemia),	  arthralgia	  and/or	  arthritis.	   	  
Arthropathy	   (symmetric	   acute	  polyarthritis)	   is	   the	  most	   common	  manifestation	   in	   adults	   (80%).	  Rash	   is	   less	   frequent	  
and	  characteristic,	  whereas	  in	  children	  it	  is	  usually	  the	  cause	  of	  infectious	  erythema,	  known	  as	  “fifth	  disease”.	  
Bicytopenia	   is	   very	   infrequent	   in	   immunocompetent	  patients.	  Nevertheless,	   in	   immunocompromised	  patients,	   PBV19	  
can	  produce	  leukopenia	  and	  transitory	  aplastic	  anaemia	  with	  reduced	  reticulocytes.	  
In	  patients	  with	  haemolytic	  diseases,	   it	  may	  cause	   transitory	  aplastic	   crises,	   although	   infection	   in	   immunosuppressed	  
patients	  may	  be	  expressed	  as	  chronic	  anaemia.	   In	  patients	  with	  malaria,	   it	   contributes	   to	   the	  pathogenesis	  of	   severe	  
anaemia	  [4,	  6].	  
In	  pregnant	  women,	  although	  infrequently,	   it	  may	  lead	  to	  severe	  foetal	  anaemia	  and	  heart	  failure,	  which	  can	  develop	  
into	  “hydrops	  fetalis”,	  and	  in	  some	  cases	  even	  foetal	  death[10].	   	  
Diagnosis	   is	   based	   on	   identification	   of	   specific	   antibodies.	   The	   gold	   standard	  molecular	   technique	   is	   DNA	   detection	  
through	  PCR	  (real-­‐time	  quantitative	  PCR),	  as	  this	  allows	  viral	  DNA	  identification	  for	  months	  or	  even	  years	  after	  the	  acute	  
infection	  episode.	   	  
Specific	   immunoglobulin	   M	   (IgM)	   antibodies	   can	   be	   detected	   as	   of	   Day	   10	   or	   12	   and	   may	   persist	   for	   2–6	   months.	  
Immunoglobulin	   G	   (IgG)	   antibodies	   appear	   15	   days	   after	   infection	   and	   can	   persist	   for	   the	   life	   of	   the	   patient.	   This	  
antibody	  overlap	  explains	  the	  common	  finding	  of	  positive	  antibodies	  to	  both	  IgG	  and	  IgM	  during	  the	  first	  weeks	  or	  even	  
months	  of	  infection	  [2,	  4].	  
In	  most	  cases,	  symptoms	  disappear	  within	  a	  few	  weeks,	  but	  in	  other	  cases	  they	  persist	  for	  months	  or	  even	  years	  [8]	  and	  
can	  evolve	  into	  chronic	  disease.	  
Acute	   viral	   disease	   can	   induce	   transient	   autoimmune	   responses	   in	   both	   adults	   and	   in	   children,	  with	  mildly	   elevated	  
antibodies	   (at	   low	   titres).	   Progression	   to	   autoimmune	   diseases	   is	   uncommon	   although	   possible	   due	   to	   T-­‐cell	  
proliferation	   and	   cytokine	   production	   with	   autoimmune	   cell	   recruitment,	   resulting	   in	   organ	   damage	   and	   chronic	  
autoimmune	  diseases.	   	   	  
In	   summary,	   the	   appearance	   of	   symptoms	   compatible	   with	   systemic	   autoimmune	   diseases,	   even	   with	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immunodeficiencies	  or	  immunomodulation	  phenomena,	  has	  been	  described	  in	  relation	  to	  several	  virus	  infections	  (HIV,	  
cytomegalovirus)	   and	   especially	   with	   PVB19,	   which	   may	   be	   involved	   in	   up	   to	   3%–4%	   of	   reactive	   arthritis	   and	   be	  
associated	   with,	   or	   even	   simulate,	   the	   symptoms	   of	   various	   diseases	   like	   rheumatoid	   arthritis,	   systemic	   lupus	  
erythematosus	   (SLE),	   systemic	   sclerosis,	   idiopathic	   juvenile	   arthritis,	   Sjögren’s	   syndrome,	   primary	   biliary	   cirrhosis,	  
autoimmune	  cytopenia	  and	  vasculitis.	   	  
	  
Case	  report	   	  
We	  present	   the	  case	  of	  a	  33-­‐year-­‐old	  male	  engineer	  who	  attended	  the	  emergency	  room	  of	  our	  hospital	   in	  May	  2012	  
because	   of	   low-­‐grade	   fever;	   severe	   odynophagia;	   polyarthritis	   in	  wrists	   and	   interphalangeal	   joints	   of	   the	   right	   hand,	  
which	   later	   also	   extended	   to	   the	   left	   hand;	   and	   arthralgia	   in	   elbows,	   knees,	   ankles,	   hips	   and	   cervical	   vertebrae,	  
associated	  with	  a	  maculopapular	  rash	  on	  the	  trunk	  of	  3–4	  days’	  evolution.	   	  
The	  relevant	  aspects	  of	  his	  medical	  history	  were	  that	  4	  years	  earlier	  he	  had	  suffered	  an	  episode	  of	  haematuria	  during	  a	  
viral	   infection	   followed	   by	   temporary	   episodes	   of	   microhaematuria	   in	   conjunction	   with	   mild	   infections,	   with	   kidney	  
function	   always	   being	   normal.	   Although	   immunoglobulin	   A	   (IgA)	   nephropathy	   was	   suspected,	   the	   study	   was	   never	  
completed.	   	  
He	  had	  also	  had	  an	  episode	  of	  paroxysmal	   supraventricular	   tachycardia	  8	   years	   earlier	   and	  was	   vaccinated	  against	  B	  
hepatitis.	   	  
He	  was	  not	  taking	  any	  drugs	  and	  had	  no	  family	  history	  of	  autoimmune	  systemic	  diseases.	   	  
One	  interesting	  fact	  was	  that	  his	  daughter	  had	  suffered	  an	  upper	  respiratory	  tract	   infection	  with	  a	  rash	  5	  days	  before	  
the	  onset	  of	  symptoms	  in	  our	  patient.	   	  
The	  physical	  examination	  only	  revealed	   inflammation	  and	  stiffness	  of	   the	  hand	   joints,	  pain	  on	  proximal	  palpitation	  of	  
interphalangeal	  joints	  and	  inflammation	  of	  the	  fifth	  finger	  of	  the	  left	  hand,	  as	  well	  as	  pain	  when	  mobilizing	  large	  joints,	  
with	  a	  very	  mild	  maculopapular	  rash	  on	  the	  trunk.	   	  
The	  only	  abnormal	  parameters	  in	  the	  blood	  test	  were	  C-­‐reactive	  protein	  (CRP)	  (78	  mg/dl)	  and	  creatine	  kinase	  (CK)	  (909	  
U/l).	  X-­‐ray	  of	  the	  hands	  and	  chest	  was	  normal.	   	  
A	   non-­‐steroidal	   anti-­‐inflammatory	   treatment	   was	   initiated	   and	   the	   patient	   was	   referred	   to	   our	   Internal	   Medicine	  
outpatient	  department.	  On	  the	  follow-­‐up	  visit	  1	  week	  later,	  the	  joint	  signs	  and	  symptoms	  had	  clearly	  improved	  and	  the	  
rash	  had	  disappeared.	   	  
Laboratory	  analysis	  showed	  persistent	  elevation	  of	  CRP	  (42.6	  mg/dl),	  erythrocyte	  sedimentation	  rate	  (ESR)	  (44),	  lactate	  
dehydrogenase	  (LDH)	  667	  U/l	  and	  fibrinogen	  (520	  mg/dl).	  All	  other	  common	  parameters	  were	  normal.	   	  
Autoimmune	  study	  results	  were	  as	  follows:	  anti-­‐nuclear	  antibodies	  (ANA)	  +1:640,	  with	  cytoplasmic	  pattern;	  anti-­‐DNAdc	  
(EliA)	   204.0	   UI/ml;	   anti-­‐smooth	   muscle	   (IFI)	   1:80;	   and	   anti-­‐cyclic	   citrullinated	   peptide	   (CCP)	   (enzyme-­‐linked	  
immunosorbent	  assay,	  ELISA)	  22.3	  U/ml.	  
Anti-­‐cardiolipin	  antibodies	  and	  lupus	  anticoagulant	  were	  positive.	  The	  rest	  of	  the	  antibodies	  (anti-­‐RNP,	  anti-­‐Sm,	  anti-­‐Ro,	  
anti-­‐La	  and	  antineutrophil	  cytoplasmic	  antibodies)	  were	  negative.	  
Bone	  scintigraphy	  revealed	  polytopic	  joint	  disease	  in	  the	  inflammatory	  phase.	   	  
Even	  though	  the	  initial	  diagnostic	  suspicion	  was	  SLE,	  with	  4	  out	  of	  11	  classificatory	  criteria	  (ACR	  1997)[11],	  several	  viral	  
serology	  tests	  were	  requested,	  and	  all	  were	  positive	  to	  parvovirus	  B19	  (IgG	  and	  IgM)	  with	  a	  viral	  load	  of	  12,600	  UI/ml.	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Under	  symptomatic	  treatment	  with	  diclofenac,	  the	  patient	  experienced	  clear	  improvement	  with	  reduction	  of	  the	  joint	  
symptoms.	  The	  blood	  tests	  were	  normal	  after	  2	  months	  with	  parvovirus	  seroconversion	  (IgM	  negative	  and	  sustained	  IgG	  
positive).	   While	   ANA	   titres	   decreased	   to	   negative,	   anti-­‐nucleosome	   antibodies	   maintained	   low	   positive	   titres	   and	  
anti-­‐DNA	  dc	  antibodies	  continued	  increasing	  until	  reaching	  354.0	  UI/ml.	   	  
At	  16	  months	  after	   the	  acute	   infection,	   the	  patient	   remained	  asymptomatic,	  without	   the	  appearance	  of	  any	  new	  SLE	  
criteria.	  The	  final	  diagnosis	  was	  self-­‐limited	  primary	  PVB19	  infection.	   	  
The	  study	  was	  completed	  with	  an	  analysis	  of	   the	  cytokines	  most	   involved	   in	   the	   response	   to	  PVB19	  according	   to	   the	  
scientific	  literature.	  Their	  determination	  in	  blood	  was	  performed	  at	  three	  different	  times	  during	  clinical	  evolution:	  at	  the	  
beginning,	  one	  month	  later	  and	  ten	  months	  later,	  once	  the	  virus	  seroconversion	  had	  been	  confirmed.	   	   	  
	  
Materials	  and	  methods	  of	  cytokine	  quantification	  
Eight	  different	  cytokines,	  interleukin	  (IL)-­‐1β,	  -­‐2,	  -­‐6,	  -­‐10,	  -­‐12	  and	  -­‐13,	  interferon	  (IFN)γ	  and	  tumour	  necrosis	  factor	  (TNF)α,	  
were	  quantified	  in	  plasma.	  A	  commercially	  available	  multiplex	  bead	  immunoassay	  based	  on	  the	  Luminex	  platform	  (Cat	  #	  
HSCYTO-­‐60SK-­‐08,	  Milliplex®	  MAP	  High	  Sensitivity,	  Millipore)	  was	  used	  according	  to	  the	  manufacturer’s	  instructions.	  All	  
samples	  were	  run	  in	  duplicate.	  The	  data	  (mean	  fluorescence	  intensity)	  were	  analyzed	  using	  a	  Luminex	  reader	  and	  the	  
mean	  concentration	  was	  calculated	  using	  a	  standard	  curve.	   	  
	   	  
Results	  
The	   elevation	   of	   IL-­‐10,	   IL-­‐6	   and	   TNFα	   cytokines,	   seen	   at	   the	   beginning	   of	   the	   symptoms,	   persisted	   after	   clinical	  
improvement.	   	  
Differences	   over	   time	  were	   observed.	  While	   IL-­‐10	   reached	  maximum	   values	   during	   clinical	   evolution,	   TNFα	   and	   IL-­‐6	  
showed	  an	  important	  increase	  at	  the	  beginning	  and	  then	  tended	  towards	  normal	  values	  in	  the	  last	  determination.	   	  
On	   the	   other	   hand,	   IL-­‐13	   and	   IFNγ	   showed	   an	  
opposite	  tendency,	  reaching	  the	  maximum	  values	  at	  
the	   time	  of	   clinical	   improvement	  and	  similar	   to	   the	  
determinations	  made	  in	  healthy	  controls.	  
Cytokine	   IL-­‐1β	   was	   virtually	   undetectable	   in	   all	  
laboratory	  tests,	  with	  levels	  lower	  than	  expected.	   	  
We	   should	   emphasize	   the	   behaviour	   of	   two	  
cytokines:	   IL-­‐12p70	   and	   IL-­‐2;	   the	   first	   being	  
practically	   normal	   during	   the	   acute	   clinical	   period,	  
with	   an	   important	   increase	   being	   observed	   during	  
confirmation	  of	  seroconversion.	  On	  the	  other	  hand,	  
IL-­‐2	   showed	   the	   opposite	   tendency,	   with	   a	   steep	  
drop	   at	   the	   moment	   that	   IL-­‐12p70	   levels	   were	  
highest.	  Figure	  1	  shows	  the	  results	  obtained.	   	  
	  
	  
Figure	  1:	  Cytokine	  pattern	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Cytokines	  with	   similar	   patterns	  have	  been	   classified	   into	   groups.	   Reference	   values	   in	   healthy	   subjects	   are	  marked	   as	  
dotted	  lines.	   	  
	  
Discussion	  
In	  the	  type	  of	  presentation	  described	  here,	  simulating	  a	  lupus	  flair,	  it	  is	  important	  to	  note	  the	  good	  evolution	  and	  clinical	  
resolution	   without	   the	   need	   for	   any	   specific	   treatment	   such	   as	   intravenous	   corticosteroids,	   immunoglobulins	   and	  
antiviral	  agents	  as	  a	  result	  of	  a	  hyperstimulation	  response	  by	  an	  immune-­‐competent	  hyperfunctional	  system.	   	  
In	   these	   cases,	   the	   involvement	  of	   the	  heart,	   kidneys	   or	   other	   viscera	  or	   organs	   is	  more	   infrequent	   than	   that	   of	   the	  
joints	  or	  skin;	  evolution	  with	  antibody	  titres	  tends	  to	  be	  low	  and	  of	  short	  duration.	   	  
Nevertheless,	   our	   case	   is	   remarkable	   for	   the	   high	   anti-­‐DNA	   antibody	   titre	   and	   its	   persistence.	   Its	   clinical,	   biological,	  
immunological	  and	  molecular	  evolution	  in	  the	  long	  term	  [12–28]	  still	  remains	  to	  be	  assessed.	  In	  addition,	  we	  observed	  
the	  temporary	  overlapping	  of	  IgG	  and	  IgM	  antibodies	  already	  described	  by	  other	  authors.	   	  
Even	   though	   the	   role	   of	   the	   host	   immune	   system	   seems	   to	   be	   crucial	   in	   the	   anti-­‐virus	   response,the	   presence	   of	   an	  
inflammatory	  cell-­‐mediated	  immune	  response,	  including	  TNFα,	  IFNγ	  and	  interleukin	  production,	  especially	  IL-­‐2	  and	  6,	  as	  
well	  as	  an	   immune	  response	  mediated	  by	  T-­‐lymphocytes	   (CD	  8+)	   [29,	  30],	  has	  also	  been	  demonstrated	   in	   this	  clinical	  
case.	  
The	  behaviour	  of	  the	  different	  cytokines	  would	  explain	  the	  patient’s	  symptoms	  over	  time.	  On	  the	  other	  hand,	  it	  would	  
support	  the	  existence	  of	  an	  idiosyncratic	  immunogenic	  ambience	  that	  favours	  immune	  events	  later	  on	  due	  to	  a	  possible	  
effect	   of	   “immunologic	   reverberation”	   once	   the	   initial	   process	   has	   been	   triggered,	   even	   having	   decreased	   the	   initial	  
symptomatology	  with	  an	  undetectable	  viral	  load.	   	  
Even	  though	  all	  these	  cytokines	  participated	  in	  the	  infectious	  process,	  its	  clinical	  correlation	  presents	  different	  aspects.	  
While	   IL-­‐6	   is	   related	   with	   autoimmune	   processes	   and	   with	   arthralgia	   [31],	   IL-­‐10	   can	   indicate	   clinical	   manifestations	  
similar	   to	   those	   typical	  of	  SLE	   [32,	  33].	   IFNγ	  determinations	  are	  of	  great	   importance,	  as	   its	  presence	  can	   indicate	   the	  
persistence	  of	  PVB19	  infection.	   	   The	  clinical	  significance	  of	  IL-­‐13	  has	  not	  yet	  been	  clarified.	   	  
IL-­‐2	   and	   IL12	   have	  mirror	   behaviour.	   The	   drastic	   IL-­‐2	   decrease	   has	   been	   correlated	  with	   the	   risk	   of	   SLE	   after	   PVB19	  
infection	  [34],	  and	  IL12	  is	  usually	  increased	  in	  SLE	  patients	  [31].	  It	  is	  remarkable	  that	  in	  our	  case,	  although	  normal	  levels	  
are	   maintained	   at	   the	   beginning,	   there	   is	   a	   drastic	   increase	   and	   maximum	   values	   are	   reached	   on	   the	   third	  
determination.	   	  
In	  summary,	  the	  higher	  prevalence	  of	  acute	  or	  past	  PVB19	  infection	  found	  in	  numerous	  autoimmune	  diseases	  could	  be	  
due	  to	  either	  a	  genetic	  base	  or	  an	  idiosyncratic	  autoimmune	  environment	  that	  has	  not	  yet	  been	  clarified	  [12,	  35–44].	  
Even	  though	  it	  has	  been	  suggested	  that	  the	  immune	  response,	  whether	  transitory	  or	  chronic,	  secondary	  to	  acute	  PVB19	  
infection	   could	   be	   involved	   in	   SLE	   pathogenesis,	   data	   favouring	   a	   superior	   prevalence	   of	   PVB19	   infection	   in	   those	  
patients	  compared	  to	  the	  general	  population	  are	  discordant.	  However,	  given	  the	  high	  proportion	  of	  bicytopenia	  in	  SLE,	  
it	  could	  be	  under-­‐diagnosed.	   	  
Cytokines	   participate	   in	   many	   important	   immunoregulation	   functions,	   playing	   an	   important	   role	   in	   immune	   system	  
modulation.	   Abnormal/aberrant	   proinflammatory	   cytokines	   or	   Th1/Th2	   response	   can	   influence	   infection	   control	   and	  
lead	  to	  viral	  persistence.	  The	  identification	  of	  the	  immune	  response	  involved	  in	  this	  process	  and	  the	  characterization	  of	  
biomarkers	  that	  could	  aid	  diagnosis	  are	  still	  to	  be	  clarified.	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Learning	  Points	  
	  
• Virus	  infections,	  especially	  PVB19,	  can	  simulate	  autoimmune	  diseases.	  
• In	  both	  cases	  (virus	  infections	  and	  autoimmune	  diseases),	  autoantibody	  and	  cytokine	  activation	  can	  be	  present.	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